ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders
(WorldNews France)

LYON, France--(BUSINESS WIRE)--Mar. 23, 2017-- Regulatory News: ERYTECH Pharma(Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company`s erymethionase program for homocystinuria, a rare and severe metabolic disorder of methionine metabolism. The collaboration will leverage FCCC`s world-class expertise to generate in vivo proof-of-concept data with erymethionase in a homocystinuria animal model. Classical homocystinuria...